Vicore Pharma Holding

16,76 SEK -1,3 %

1 investor følger denne virksomhed

Vicore Pharma Holding is a pharmaceutical company. The company conducts research and development of molecules with agnostic effect, in industry terms called Renin-Angiotensin System (RAS), which affects the fluid and salt balance in the body. Vicore Pharma usually enters into licensing agreements with other pharmaceutical partners in the industry and has business operations at a global level. The company was founded in 2000 and is headquartered in Gothenburg.

Omsætning

EBIT %

P/E

Udbytteafkast, %

Kursmål

Anbefaling

Opdateret

NASDAQ Stockholm

VICO

Daglig lav / høj pris

16,6 / 17 SEK

Markedsværdi

1,37 mia. SEK

Aktieomsætning

348,87 t SEK

Volumen

21 t

Seneste videoer

Vicore Pharma, Capital Markets Day, 2022

06.09.2022

Vicore Pharma, Capital Markets Day, 2022

23.02.2022

Vicore Pharma, Webcast with teleconference, 2022

10.02.2022

Finanskalender

Delårsrapport

24.08.2023

Delårsrapport

02.11.2023

Årsrapport

28.02.2024

Viser Alle indholdstyper

Vicore further strengthens patent protection for C21

Pressemeddelelse07.06.2023

Vicore Pharma Holding

Seneste videoer

Finanskalender

Vicore further strengthens patent protection for C21

Vicore obtains significant new patent protection for C21 in the US

Vicore reports new 36-week data from the AIR trial demonstrating sustained disease stabilization and increase in lung function in IPF patients

Vicore to host webcast with updated AIR trial results after presentation at the ATS congress

Vicore strengthens its Board of Directors

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

Correction: Interim report January-March 2023

Interim report January-March 2023

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

Vicore Pharma publishes the Annual Report for 2022

Vicore to announce AIR trial update at the ATS congress on May 21st

Vicore receives Innovation Passport designation by the UK regulatory agency MHRA for C21 in IPF

Year-end report 2022

Vicore Pharma Holding AB: Increase of number of shares and votes in Vicore Pharma

Vicore Pharma Holding AB: Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

Vicore Pharma Holding AB: Vicore intends to carry out a directed share issue

Vicore Pharma Holding AB: Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

Vicore Pharma Holding AB: Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

Redeye: Vicore - Our Q3 Comment